Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bearish -35

Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty - Quiver Quantitative

📉 Moderna shares slid 7.8% today as investors digested a $950 million patent settlement charge expected in Q1 2026.

⚖️ The FDA issued a Refusal-to-File letter for the mRNA-1010 seasonal flu vaccine, creating regulatory uncertainty over U.S. launch timing.

📊 President Stephen Hoge sold 160,009 shares ($7.8M) and CLO Shannon Thyme Klinger sold 13,885 shares in the last six months.

🏦 FMR LLC added over $464M to its Moderna position in Q4 2025, while UBS Asset Management cut its stake by nearly 80%.

📈 Analyst price targets remain mixed, with Piper Sandler setting a high target of $69.00 against Morgan Stanley's lower target of $28.00.

⚠️ The FDA refusal does not cite safety or efficacy issues but delays the start of BLA review for the flu vaccine program.

Bullish Signals
  • The patent litigation settlement resolves major legal uncertainty surrounding COVID-19 vaccines, removing a long-term overhang despite the immediate cash cost.
  • The FDA's Refusal-to-File letter explicitly does not cite safety or efficacy concerns for the investigational flu vaccine mRNA-1010.
  • Major institutional investors like FMR LLC and Capital World Investors significantly increased their Moderna holdings in Q4 2025, signaling confidence in long-term prospects.
  • Piper Sandler analyst Edward Tenthoff issued an 'Overweight' rating with a price target of $69.00 on February 23, 2026.
Risk Factors
  • Moderna faces a $950 million accounting charge expected in the first quarter of 2026 due to patent litigation settlements.
  • The FDA's Refusal-to-File letter for the seasonal flu vaccine (mRNA-1010) leaves U.S. timing uncertain and delays regulatory review.
  • Significant insider selling occurred recently, with President Stephen Hoge offloading 160,009 shares and CLO Shannon Thyme Klinger selling 13,885 shares.
  • Institutional sentiment is mixed, with UBS Asset Management reducing its position by 79.7% and Citadel Advisors cutting holdings by 70.9% in Q4 2025.
  • Multiple Wall Street firms issued sell or underperform ratings, including JP Morgan (Underweight), B of A Securities (Underperform), and Leerink Partners (Underperform).
Full Analysis
Moderna (MRNA) shares fell 7.8% in a post-rally pullback as investors weighed recent legal-cost clarity against fresh regulatory uncertainty regarding its standalone flu vaccine. The selloff appears driven by profit-taking and sentiment shifts rather than a single new headline, with traders reassessing the timeline for U.S. franchise expansion after an FDA Refusal-to-File letter. The company disclosed a broad settlement resolving major COVID-19 vaccine-related patent litigation, which includes a $950 million charge expected in the first quarter of 2026 and additional contingent payments. While this resolves uncertainty, the immediate accounting impact pressures near-term sentiment. Simultaneously, Moderna received a Refusal-to-File letter from the FDA for its investigational seasonal influenza vaccine (mRNA-1010), leaving U.S. timing uncertain despite the company stating the letter did not cite safety or efficacy concerns. Insider trading data shows significant selling pressure over the last six months, with President Stephen Hoge selling 160,009 shares and Chief Legal Officer Shannon Thyme Klinger selling 13,885 shares. Institutional investors are also divided, with major firms like FMR LLC and Capital World Investors adding substantial positions in Q4 2025, while others like UBS Asset Management and Citadel Advisors significantly reduced their holdings.